Reflecting the complexity of high-risk neuroblastoma, this session covers a wide range of subjects that are currently [at the time of NPGS 2022] being researched. Prof. Jan Molenaar gives an introduction to precision medicines and how new targets are identified. Dr. Sara Federico and Dr. Rajen Mody present results of a number of clinical trials looking at new treatments for relapsed disease. Dr. Steven DuBois rounds off the session with an overview of the multiple strategies underway to improve frontline treatments.
This is a recorded presentation from the 2022 symposium.